Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Palovarotene in Healthy Japanese and Non-Asian Subjects
NCT04829786Phase 1Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Sep 2015
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial of palovarotene in fibrodysplasia ossificans progressiva (FOP) (2 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoints: Maximum (peak) plasma drug concentration, Time to reach maximum (peak) plasma concentration and 6 more. Started Sep 2015; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT04829786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829786.